 | Up a level |
Pabst, Thomas; Papayannidis, Cristina; Demirkan, Fatih; Doronin, Vadim; Fogliatto, Laura M; Guttke, Christina; Gyan, Emmanuel; Hamad, Nada; Herrera, Pilar; Hultberg, Anna; Jacobs, Julie; Johnson, Amy J; Langlois, Angélique; Ma, Xuewen; Martinelli, Giovanni; Arnan, Montserrat; Müller, Rouven; Nottage, Kerri; Ofran, Yishai; Özcan, Muhit; ... (2023). Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study. The Lancet. Haematology, 10(11), e902-e912. Elsevier 10.1016/S2352-3026(23)00207-7
Shumilov, Evgenii; Shakhanova, Inna; Flach, Johanna; Schmidt, Nicole; Buerki, Susanne; Legros, Myriam; Kronig, Marie-Noëlle; Ofran, Yishai; Gerull, Sabine; Medinger, Michael; Mansouri Taleghani, Behrouz; Passweg, Jakob; Halter, Jörg; Bacher, Ulrike; Pabst, Thomas (2022). Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation. Bone marrow transplantation, 57(2), pp. 224-231. Springer Nature 10.1038/s41409-021-01521-5
